Working... Menu

Exploratory Clinical Study of Apatinib and PD-1 in Treating Advanced Gastric Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03954756
Recruitment Status : Not yet recruiting
First Posted : May 17, 2019
Last Update Posted : May 17, 2019
Information provided by (Responsible Party):
Henan Cancer Hospital

Brief Summary:
The Purpose of This Study is to Evaluate the Efficacy and Safety of Apafitini Combined With PD1 in Patients With Advanced Gastric Cancer After Second-line Treatment Failure, Thus Providing More Options for Patients With Advanced Gastric Cancer.

Condition or disease Intervention/treatment Phase
Advanced Gastric Cancer Drug: Apatinib and PD1 Phase 2

Detailed Description:
Patients will received apatinib orally every day and PD-1 200mg (3mg/kg for underweight patients) iv every 2 weeks. The efficacy and safety will be observed.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 35 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Clinical Study of the Combination of Apatinib and PD1 in Treating Advanced Gastric Cancer
Estimated Study Start Date : June 1, 2019
Estimated Primary Completion Date : June 1, 2021
Estimated Study Completion Date : June 1, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Stomach Cancer

Arm Intervention/treatment
Experimental: apatinib and PD-1
Every patients will received apatinib orally every day and PD-1 200mg (3mg/kg for underweight patients) iv every 2 weeks until disease progression or intolerance of side effect
Drug: Apatinib and PD1
  1. Apatinib starting dose of 500mg, qd, oral, taken half an hour after a meal
  2. PD-1 was administered 200mg (3mg/kg for underweight patients) iv every 2 weeks.

Primary Outcome Measures :
  1. Overall survival rate [ Time Frame: up to 2 year ]

Secondary Outcome Measures :
  1. Objective response rate [ Time Frame: up to 2 year ]

    Defined as the proportion of patients with a documented complete response, and partial response (CR

    + PR

  2. Disease control rate [ Time Frame: up to 2 year ]
    The time from the start of randomization to the first tumor recurrence/metastasis or the death of the subject for any reason

  3. Overall survival [ Time Frame: up to 2 year ]
    From date of randomization until the date of death from any cause

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients join the study voluntarily, sign a consent form, have good compliance, and comply with follow-up.
  2. To be confirmed to meet the clinical diagnosis standard, histologically or cytologically confirmed advanced Gastric Cancer.
  3. Failure of the second-line standard treatment regimen (disease progression), >14 days from the last chemotherapy, chemotherapy regimen including fluorouracil (5-FU / capecitabine / teggio), oxaliplatin and irinotecan; Acceptable or not received bevacizumab/cetuximab/regofenib treatment.
  4. Aged 18-70 years old, both genders.
  5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1.
  6. Life expectancy of at least 3 months.
  7. Patients must have at least 1 lesion that is measurable using RECIST v1.1 criteria.If the lesion receiving local therapy (radiotherapy, radiofrequency, interventional therapy, etc.) is the only lesion, definite imaging progress is required.
  8. the main organ functions of the patient shall meet the following standards within 7 days before treatment:Blood routine examination standard (without blood transfusion within 7 days before enrollment)Hemoglobin ≥ 70 g/L; Absolute neutrophil count (ANC) ≥1.5×109/L; Platelet count ≥ PLT)≥80×109/L;Biochemical examination shall meet the following standards:serum total bilirubin (TBIL)≤1.5 times the upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×upper limit of normal(ULN);Serum creatinine (Cr)≤1.5ULN or creatinine removal rate (CCr)≥60ml/min;
  9. Women of childbearing age should agree to use contraceptives (such as intrauterine devices, contraceptives or condoms) during the study period and within 6 months after the end of the study; the serum or urine pregnancy test is negative within 7 days prior to study enrollment and must be Non-lactating patients; males should agree to patients who must use contraception during the study period and within 6 months after the end of the study period。

Exclusion Criteria:

  1. Hypertension and unable to be controlled within normal level following treatment of anti-hypertension agents(within 3 months): systolic blood pressure > 140 mmHg, diastolic blood pressure > 90 mmHg;
  2. Diabetes blood sugar control is poor;
  3. Acute phase of cerebral infarction, or recovery period <2 months;
  4. Has a variety of factors that affect the absorption of oral drugs (such as inability to swallow, nausea and vomiting, chronic diarrhea and intestinal obstruction);
  5. Patients with a risk of gastrointestinal bleeding may not be enrolled, including the following: (1) active digestive ulcer lesions and fecal occult blood (++); (2) nausea and hematemesis within 2 months Medical history. Simple fecal occult blood (+) is not an exclusion criterion;
  6. Coagulation abnormalities (INR>1.5×ULN,APTT>1.5×ULN),with bleeding tendency;
  7. Urine protein ≥ ++ or confirmed 24 hour urine protein quantitation > 1.0 g;
  8. Pregnant or lactating women;
  9. Within 2 weeks after treatment with cytotoxic drugs and radiotherapy;Has taken two or more oral targeted drugs;
  10. Except for other malignant tumors, basal cell carcinoma of the skin and cervical cancer in situ in the past 5 years;
  11. The investigator believes that there are any conditions that may damage the subject or result in the subject being unable to meet or perform the research request;
  12. Patients with severe liver and kidney dysfunction (grade 4) should be excluded;
  13. Those who are allergic to any component of apafitini mesylate should be excluded;
  14. Mental disorders history, or psychotropic drug abuse history;
  15. Previous use of regorafenib is not an exclusion criterion;
  16. According to the investigator's judgment, there are people with concomitant diseases that seriously endanger the safety of the patient or affect the patient's completion of the study;
  17. Surgery was performed within 4 weeks prior to the start of treatment, or patients with major trauma or fractures. Or there is an unhealed wound before treatment;
  18. Patients with severe heart disease, such as grade III or above (NYHA standard) congestive heart failure, or grade III or above (CCS standard) angina, or a history of myocardial infarction within 6 months prior to treatment, or an arrhythmia requiring medication;
  19. The patient has brain metastasis, meningeal metastasis;
  20. Active HBV infection and rejection of formal antiviral therapy;
  21. Active tuberculosis;
  22. Participants who have participated in any drug or medical device clinical trial within 1 month prior to the trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03954756

Layout table for location contacts
Contact: Ning Li 13526501903

Sponsors and Collaborators
Henan Cancer Hospital

Layout table for additonal information
Responsible Party: Henan Cancer Hospital Identifier: NCT03954756     History of Changes
Other Study ID Numbers: APD-L0315
First Posted: May 17, 2019    Key Record Dates
Last Update Posted: May 17, 2019
Last Verified: May 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Stomach Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Stomach Diseases
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action